Mucosal immunity and vaccines

Nature Medicine

Volumn 11, Issue 4S, 2005, Pages S45-

  Holmgren, Jan ^a   Czerkinsky, Cecil ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALLERGEN; CHEMOKINE RECEPTOR CCR9; CHOLERA TOXIN; CHOLERA VACCINE; ENTEROTOXIN; GAMMA INTERFERON; HOMING RECEPTOR; HOUSE DUST ALLERGEN; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 4; ISCOM; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; POLLEN ANTIGEN; RAGWEED ANTIGEN; ROTAVIRUS VACCINE; SECRETORY IMMUNOGLOBULIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TYPHOID VACCINE; VACCINE;

ALLERGIC DISEASE; ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BYSTANDER EFFECT; CALICIVIRUS; CHLAMYDIA TRACHOMATIS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DANDER; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GRASS; HASHIMOTO DISEASE; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; INFLUENZA VIRUS; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE INFECTION; LYMPHOID TISSUE; MACROPHAGE; MOUSE; MUCOSAL IMMUNITY; MYASTHENIA GRAVIS; MYCOPLASMA PNEUMONIAE; NATURAL KILLER CELL; NEISSERIA GONORRHOEAE; NONHUMAN; PARIETARIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; ROTAVIRUS; SALMONELLA TYPHI; SHIGELLA; SYSTEMATIC REVIEW; T LYMPHOCYTE; UVEITIS; VIBRIO CHOLERAE; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASE CONTROL; DRUG DELIVERY SYSTEMS; HUMANS; HYPERSENSITIVITY; IMMUNITY, MUCOSAL; LYMPHOID TISSUE; VACCINES;

AMBROSIA; ANIMALIA; CALICIVIRIDAE; CHLAMYDIA TRACHOMATIS; CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI; HELICOBACTER PYLORI; HERPES; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; MYCOPLASMA PNEUMONIAE; NEISSERIA GONORRHOEAE; PARIETARIA; RESPIRATORY SYNCYTIAL VIRUS; ROTAVIRUS; SALMONELLA TYPHI; SHIGELLA; SIMPLEXVIRUS; VIBRIO CHOLERAE;

EID: 17644371966     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1213     Document Type: Article

References (100)

1. Mestecky, J. et al. (eds). Mucosal Immunology 3rd edn. (Academic Press, San Diego, 2005).
2. Mowat, A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3, 331-341 (2003).
3. Kiyono, H. & Fukuyama, S. NALT- versus Peyer’s-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4, 699-710 (2004).
4. Ishikawa, H., Saito, H., Suzuki, K., Oida, T. & Kanamori, Y. New gut associated lymphoid tissue “cryptopatches” breed murine intestinal intraepithelial T cell precursors. Immunol. Res. 20, 243-250 (1999).
5. Guy-Grand, D. et al. Extrathymic T cell lymphopoiesis: Ontogeny and contribution to gut intraepithelial lymphocytes in athymic and euthymic mice. J. Exp. Med. 197, 333-341 (2003).
6. Bilsborough, J. & Viney, J.L. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. Gastroenterology 127, 300-309 (2004).
7. Iwasaki, A. & Kelsall, B.L. Freshly isolated Peyer’s patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190, 229-239 (1999).
8. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004).
9. Kunkel, E.J. & Butcher, E.C. Plasma-cell homing. Nat. Rev. Immunol. 3, 822-829 (2003).
10. Campbell, D.J., Debes, G.F., Johnston, B., Wilson, E. & Butcher, E.C. Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. 15, 277-286 (2003).
11. Stagg, A.J., Kamm, M.A. & Knight, S.C. Intestinal dendritic cells increase T cell expression of a4ß7 integrin. Eur. J. Immunol. 32, 1445-1454 (2002).
12. Mora, J.R. et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 424, 88-93 (2003).
13. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).
14. Quiding, M. et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses, gamma-interferon production, and evokes local immunological memory. J. Clin. Invest. 88, 143-148 (1991).
15. Eriksson, K. et al. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect. Immun. 66, 5889-5896 (1998).
16. Kozlowski, P.A., Cu-Uvin, S., Neutra, M.R. & Flanigan, T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65, 1387-1394 (1997).
17. Jertborn, M., Nordström, I., Kilander, A., Czerkinsky, C. & Holmgren, J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69, 4125-4128 (2001).
18. Johansson, E.L., Bergquist, C., Edebo, A., Johansson, C. & Svennerholm, A.-M. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 22, 984-990 (2004).
19. Johansson, E.-L., Wassen, L., Holmgren, J., Jertborn, M. & Rudin, A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun. 69, 7481-7486 (2001).
20. Nardelli-Haefliger, D. et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95, 1128-1137 (2003).
21. Gockel, C.M., Bao, S. & Beagley, K.W. Transcutaneous immunization induces muco- sal and systemic immunity: A potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37, 537-544 (2000).
22. Yuan, Q. & Walker, W.A. Innate immunity of the gut: Mucosal defense in health and disease. J. Pediatr. Gastroenterol. Nutr. 38, 463-473 (2004).
23. Lycke, N., Eriksen, L. & Holmgren, J. Protection against cholera toxin after oral immunization is thymus-dependent and associated with intestinal production of neutralizing IgA antitoxin. Scand. J. Immunol. 25, 413-419 (1987).
24. Hornquist, C.E., Ekman, L., Grdic, K.D., Schon, K. & Lycke, N.Y. Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J. Immunol. 155, 2877-2887 (1995).
25. Macpherson, A.J. et al. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288, 2222-2226 (2000).
26. Stoel, M. et al. Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasma- blasts. J. Immunol. 174, 1046-1054 (2005).
27. Goodrich, M.E. & McGee, D.W. Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. Cytokine 10, 948-955 (1998).
28. Asano, T. et al. Molecular analysis of B cell differentiation in selective or partial IgA defiency. Clin. Exp. Immunol. 136, 284-290 (2004).
29. Klavinskis, L.S. et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J. Immunol. 157, 2521-2527 (1996).
30. Staats, H.F. et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167, 5386-5394 (2001).
31. Belyakov, I.M., Hammond, S.A., Ahlers, J.D., Glenn, G.M. & Berzofsky, J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113, 998-1007 (2004).
32. Franco, M.A. & Greenberg, H.B. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J. Virol. 69, 7800-7806 (1995).
33. Bender, B.S., Croghan, T., Zhang, L. & Small, P.A., Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 175, 1143-1145 (1992).
34. Buzoni-Gatel, D., Lepage, A.C., Dimier-Poisson, I.H., Bout, D.T. & Kasper, L.H. Adoptive transfer of gut intraepithelial lymphocytes protects against murine infection with Toxoplasma gondii. J. Immunol. 158, 5883-5889 (1997).
35. Bowen, J.C., Nair, S.K., Reddy, R. & Rouse, B.T. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 81, 338-342 (1994).
36. + T cell responses. J. Immunol. 166, 1106-1113 (2001).
37. Johansson, M., Schön, K., Ward, M. & Lycke, N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect. Immun. 65, 1032-1044 (1997).
38. Ermak, T.H. et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 188, 2277-2288 (1998).
39. Harandi, A.M., Svennerholm, B., Holmgren, J. & Eriksson, K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. Virol. 75, 6705-6709 (2001).
40. Wu, H.Y. & Weiner, H.L. Oral tolerance. Immunol. Res. 28, 265-284 (2003).
41. Whitacre, C.C., Gienapp, I.E., Orosz, C.G. & Bitar, D.M. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 147, 2155-2163 (1991).
42. Chen, Y. et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376, 177-180 (1995).
43. Ngan, J. & Kind, L.S. Suppressor T cells for IgE and IgG in Peyer’s patches of mice made tolerant by the oral administration of ovalbumin. J. Immunol. 120, 861-865 (1978).
44. Polanski, M., Melican, N.S., Zhang, J. & Weiner, H.L. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J. Autoimmun. 10, 339-346 (1997).
45. Groux, H. et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
46. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A. & Weiner, H.L. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
47. Thornton, A.M. & Shevach, E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
48. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
49. Klein, L., Khazaie, K. & von Boehmer, H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc. Natl Acad. Sci. USA 100, 8886-8891 (2003).
50. + regulatory T cells in vivo. J. Exp. Med. 198, 249-258 (2003).
51. + T helper cells. Eur. J. Immunol. 34, 1303-1311 (2004).
52. Huang, C.T. et al. Role of LAG-3 in regulatory T cells. Immunity 21, 503-513 (2004).
53. McMenamin, C., Pimm, C., McKersey, M. & Holt, P.G. Regulation of IgE responses to inhaled antigen in mice by antigen-specific yS T cells. Science 265, 1869-1871 (1994).
54. Hanninen, A. & Harrison, L.C. yS T cells as mediators of mucosal tolerance: The autoimmune diabetes model. Immunol. Rev. 173, 109-119 (2000).
55. Crispe, I.N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3, 51-62 (2003).
56. + invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J. Immunol. 173, 1043-1050 (2004).
57. Akbari, O., DeKruyff, R.H. & Umetsu, D.T. Pulmonary dendritic cells producing IL- 10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2, 725-731 (2001).
58. Zhaori, G., Sun, M. & Ogra, P.L. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J. Infect. Dis. 158, 160-165 (1988).
59. World Health Organization. Cholera vaccines. WHO position paper. Wkly. Epidemiol. Rec. 76, 117-124 (2001).
60. Holmgren, J. & Bergquist, C. Oral B subunit killed whole-cell cholera vaccines. in New Generation Vaccines 3rd edn. (ed. Levine, M.M. et al.) 499-510 (Marcel Dekker, New York, 2004).
61. Lucas, M. et al. High-level effectiveness of a mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med. 352, 757-767 (2005).
62. Ali, M. et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh. Lancet (in the press).
63. Trach, D.D. et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349, 231-235 (1997).
64. Levine, M.M. & Kaper, J.B. Live oral cholera vaccine: From principle to product. Bull. Inst. Pasteur93, 243-253 (1995).
65. Richie, E. et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103- HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18, 2399-2410 (2000).
66. Acharya, I.L. et al. Prevention of typhoid fever in Nepal with the Vi capsular polysac- charide of Salmonella typhi. A preliminary report. N. Engl. J. Med. 317, 1101-1104 (1987).
67. Klugman, K. et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14, 435-438 (1996).
68. Yang, H.H. et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in Southwestern China. Bull. World Health Organ. 79, 625-631 (2001).
69. Levine, M.M. et al. Duration of efficacy of Ty21a attenuated Salmonella typhi live oral vaccine. Vaccine 17, S22-S27 (1999).
70. Svennerholm, A.M. & Steele, D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. BestPract. Res. Clin. Gastroenterol. 18, 421-445 (2004).
71. De Vos, B. et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23, S179-S182 (2004).
72. Belshe, R., Lee, M.-S., Walker, R.E., Stoddard, J. & Mendelman, P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3, 643-654 (2004).
73. Cox, R.J., Brokstad, K.A. & Ogra, P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1-15 (2004).
74. Chaillous, L. et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial. Lancet 356, 545-549 (2000).
75. Wiendl, H. & Hohlfeld, R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs 16, 183-200 (2002).
76. Postlethwaite, A.E. Can we induce tolerance in rheumatoid arthritis? Curr. Rheumatol. Rep. 3, 64-69 (2001).
77. Sun, J.B., Rask, C., Olsson, T., Holmgren, J. & Czerkinsky, C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl Acad. Sci. USA 93, 7196-7201 (1996).
78. Bergerot, I. et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl Acad. Sci. USA 94, 4610-4614 (1997).
79. Tarkowski, A., Sun, J.-B., Holmdahl, R., Holmgren, J. & Czerkinsky, C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagencholera toxoid conjugate vaccine. Arthritis Rheum. 42, 1628-1634 (1999).
80. Phipps, P.A. et al. Prevention of mucosally induced uveitis with a HSP60- derived peptide linked to cholera toxin B subunit. Eur. J. Immunol. 33, 224-232 (2003).
81. Tamura, S., Hatori, E., Tsuruhara, T., Aizawa, C. & Kurata, T. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine 15, 225-229 (1997).
82. Stanford, M. et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit preventing relapses of uveitis in Behcet’s disease. Clin. Exp. Immunol. 137, 201-208 (2004).
83. Wilson, D.R., Torres Lima, M. & Dirham, S.R. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy 60, 4-12 (2005).
84. Di Rienzo, V. et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A 10-year prospective study. Clin. Exp. Allergy 33, 206-210 (2003).
85. Mastrandrea, F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am. J. Clin. Dermatol. 5, 281-294 (2004).
86. Vrtala, S., Focke-Tejkl, M., Swoboda, I., Kraft, D. & Valenta, R. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 32, 313-320 (2004).
87. Holmgren, J., Czerkinsky, C., Eriksson, K. & Harandi, A. Mucosal immunisation and adjuvants: A brief overview of recent advances and challenges. Vaccine 21, S89-S95 (2003).
88. Schoen, C., Stritzker, J., Goebel, W. & Pilgrim, S. Bacteria as DNA vaccine carriers for genetic immunization. Int. J. Med. Microbiol. 294, 319-335 (2004).
89. Vajdy, M. et al. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol. Cell Biol. 82, 617-627 (2004).
90. Shi, W., Liu, J., Huang, Y. & Qiao, L. Papillomavirus pseudovirus: A novel vaccine to induce mucosal and systemic cytotoxic T lymphocyte responses. J. Virol. 75, 10139-10148 (2001).
91. Guerrero, R.A. et al. Recombinant Norwalk virus-like particles administered intrana- sally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75, 9713-9722 (2001).
92. Niikura, M. et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 293, 273-280 (2002).
93. Holmgren, J., Harandi, A.M. & Czerkinsky, C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines 2, 205-217 (2003).
94. Plant, A. & Williams, N.A. Modulation of the immune response by the cholera-like enterotoxins. Curr. Top. Med. Chem. 4, 509-519 (2004).
95. Pizza, M. et al. Mucosal vaccines: Non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534-2541 (2001).
96. Lu, X., Clements, J.D. & Katz, J.M. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20, 1019-1029 (2002).
97. Sanchez, J., Wallerström, G., Fredriksson, M., Angstrom, J. & Holmgren, J. Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J. Biol. Chem. 277, 33369-33377 (2002).
98. Lycke, N. From toxin to adjuvant: The rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell. Microbiol. 6, 23-32 (2004).
99. McCluskie, M.J., Weeratna, R.D., Payette, P.J. & Davis, H.L. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit. Rev. Immunol. 21, 103-120 (2001).
100. Harandi, A.M. & Holmgren, J. CpG DNA as a potent inducer of mucosal immunity: Implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr. Opin. Investig. Drugs 5, 141-145 (2004).